CytomX Therapeutics (CTMX) Receivables - Net (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Receivables - Net came in at $646000.0 in Q1 2026, down 66.97% YoY from $2.0 million in Q1 2025, and down 28.22% on a QoQ basis from $900000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Receivables - Net (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Receivables - Net data on file, last reported at $646000.0 in Q1 2026.
- Quarterly Receivables - Net fell 66.97% year-over-year to $646000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646000.0 (down 66.97% YoY) and the FY2025 annual result came in at $2.0 million, down 35.13% from the prior year.
- Receivables - Net slipped to $646000.0 in Q1 2026, from $900000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $36.0 million in Q4 2022 to a low of $646000.0 in Q1 2026.
- A 5-year average of $4.4 million and a median of $1.9 million in 2025 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net jumped 4398.25% — and 2023, when it plunged 93.89%.
- Tracing CTMX's Receivables - Net over 5 years: stood at $36.0 million in 2022, then sank by 93.89% to $2.2 million in 2023, then slumped by 50.0% to $1.1 million in 2024, then dropped by 18.18% to $900000.0 in 2025, then slipped by 28.22% to $646000.0 in 2026.
- The last three Receivables - Net figures came in at $646000.0 (Q1 2026), $900000.0 (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.50 Mn |
| Jun 30, 2026 | 37.50 Mn |
| Mar 31, 2026 | 646,000.00 |
| Mar 31, 2026 | 646,000.00 |
| Dec 31, 2025 | 900,000.00 |
| Dec 31, 2025 | 900,000.00 |
| Sep 30, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 3.35 Mn |
| Sep 30, 2024 | 3.35 Mn |
| Jun 30, 2024 | 2.78 Mn |
| Jun 30, 2024 | 2.78 Mn |
| Mar 31, 2024 | 13.18 Mn |
| Mar 31, 2024 | 13.18 Mn |